MLTX Q2 2023 Earnings — MoonLake Immunotherapeutics Revenue & Financial Results | Market Cap Arena

MLTXMoonLake Immunotherapeutics

$1B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$13M

Net Income

-$10M

EPS (Diluted)

$-0.23

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$507M

Total Liabilities

$8M

Stockholders' Equity

$490M

Cash & Equivalents

$502M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$13M	-$18M	+25.3%
Net Income	-$10M	-$12M	+16.3%

Revenue Segments

License

$300M100%